Pozen (POZN -1.1%) gives back the early morning gains it racked up today, after reporting...
Nov 16 2012, 11:37 ET
Pozen (POZN -1.1%) gives back the early morning gains it racked up today, after reporting positive Phase I testing results of its PA8140-102 drug candidate - a proprietary combination of aspirin and omeprazole, used to treat acid reflux, pectic ulcer and other gastroesophageal problems. It also says that it's successfully manufactured the PA8140 tablet batches, required for the primary NDA stability program. POZN is targeting an NDA submission for the drug no later than the end of April 2013.